Fund Your Cancer Drug Trials: NIH Grants Up to $5M
Posted: January 10, 2019
This grant closed on May 22, 2019. We have found similar active grants for you below.
Summary
NCI is funding early-phase clinical trials for new cancer drug agents. This grant supports research teams with the infrastructure to conduct Phase 0, 1, 2, and pilot trials for NCI Investigational New Drugs.
Eligibility
Full Description
The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to continue support for the Experimental Therapeutics Clinical Trials Network (ETCTN) for the efficient and comprehensive conduct of early phase clinical trials of NCI Investigational New Drug (IND) agents. The ETCTN is designed to assure the availability of investigators and programs with expertise in early drug development and translational research for this purpose. This FOA solicits UM1 cooperative agreement applications from appropriate multidisciplinary groups that can assemble an appropriate infrastructure and conduct phase 0, phase 1, phase 2, pilot and other experimental therapeutics clinical trials involving agents for which the NCIs Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP) received IND status. The FOA is open to any qualified applicant regardless of whether they have been previously associated with the ETCTN.